MİYAZ SİNEKLERİ LARVALARININ YARA TEDAVİSİNDE KULLANILMASI

Year 2017, Volume: 8 Issue: 32, 20 - 28, 31.12.2017

Mehmet Yaman , Aykut Zerek

https://doi.org/10.17944/mkutfd.311929

Cited By: 1

Abstract

Antibiyotiklere dirençli
bakteri suşlarının artması ile antibakteriyel bileşenlerin etkilerinin
araştırılması daha da önemli hale gelmiştir. Maggot terapi, nekrotik dokulara
affinite duyan maggot adı da verilen miyaz sinek larvalarının yara tedavisinde
kullanımına dayalı bir metottur. Nekrotik dokuların debridmanında çok etkili
olması, güvenli ve kolay uygulanabilmesi, düşük maliyeti ve antibiyotiğe
dirençli enfeksiyonlarda bile etkili olabilmesi maggot terapinin
avantajlarıdır. Bu avantajları nedeniyle Maggot terapinin popülaritesi dünya
genelinde birçok ülkede hızlı bir şekilde artmaktadır. Bu derlemede Miyaz sinek
larvaları ve Maggot terapi hakkında bilgi verilmiştir.

Keywords

Antibiyotik direnci, miyaz sinek larvaları, maggot terapi

USE OF MYIASIS FLIES LARVAE IN THE WOUND TREATMENT

Abstract

Investigation of the effects of
antibacterial compounds have become more important with the increasing of
antibacterial-resistant strains of bacteria. Maggot therapy is a method based
on the use of myiasis fly larvae also called maggot which affinity necrotic
tissue in wound treatment. The use and popularity of maggot therapy is
increasing rapidly in many countries throughout the world. The advantages of maggot therapy which include its
profound efficacy in debriding necrotic tissue, its safety and its simplicity,
its low cost and its effectiveness even in the context of antibiotic-resistant
infections. Because of these advantages popularity of maggot therapy is
increasing rapidly in many countries throughout the World. In
this review, information was given about myiasis flies larvae and  maggot
therapy.

Keywords

Antibiotic resistance, myiasis flies larvae, maggot therapy

References

• 1. Doğandemir G. Lucilia sericata’nın Kronik Yaralarda Kolonize Olan Mikroorganizmalar Üzerindeki Antimikrobiyal Etkinliğinin Araştırılması. Tıpta Uzmanlık Tezi, Genelkurmay Başkanlığı Gülhane Askeri Tıp Akademisi, Askeri Tıp Fakültesi, Ankara: Tıbbi Mikrobiyoloji Anabilim Dalı Başkanlığı, 2010.
• 2. Sayın İpek DN. Diyarbakır ve Çevresinde Eksternal Myiasis Vakaları, Bazı Parametreler ve Tedavileri ile Etkenlerin Yayılışı, Mevsimsel Aktiviteleri ve Biyolojileri Üzerine Araştırmalar. Doktora Tezi, Fırat Üniversitesi Sağlık Bilimleri Enstitüsü Parazitoloji Anabilim Dalı, 2010.
• 3. Orunç Kılınç Ö, Oğuz B, Sona A, Biçek K, Özdal N ve ark. Bir Köpekte Wohlfahrtia magnifica (Schiner, 1862; Diptera: Sarcophagidae) Larvalarından İleri Gelen Travmatik Myiasis Olgusu, Animal Health Prod and Hyg, 2013; 2(2) : 209 – 211.
• 4. Zumpt F. Myiasis in man and animals in the old world. Butterwoths & Co. ltd. London, 1965.
• 5. Soulsby EJL. Helminths, arthropods and protozoa of domesticated animals. Bailliere Tindall, London, 1986.
• 6. Kettle DS. Medical and Veterinary Entomology. CAB International, Wallingford, 1990.
• 7. Oytun HŞ. Tıbbi Entomoloji. Ank Üniv Tıp Fak Yay Güzel İst Matb İstanbul, 1961.
• 8. Baumgartner DL. Review of Chrysomya rufifacies (Diptera: Calliphoridae). J Med Entomol, 1993; 30 (2): 338-352.
• 9. Fiescher OA. Blowfly of the genera Calliphora, Lucilia and Protophormia (Diptera, Calliphoridae) in South- Moravian urban and rural areas with respectto Lucilia bufonivora Moniez, 876, Acta Vet Brno 69, 2000; 225-231.
• 10. Sherman RA, Hall MJ, Thomas S. Medicinal maggots: an ancient remedy for some contemporary afflictions. Annu Rev Entomol, 2000; 45: 55–81.
• 11. Sherman RA, Grassberger M, Gileva OS, Kim CMH, Mumcuoğlu KY (Editors), Biotherapy - History, Principles and Practice, Springer Science+Business Media Dordrecht, 2013.
• 12. Nigam Y, Bexfield A, Thomas S, Ratcliffe NA. Maggot Therapy: The Science and Implication for CAM Part I – History and Bacterial Resistance. Evid-Based Compl Alt, 2006; 3 (2): 223–227.
• 13. Whitaker IS, Twine C, Whitaker MJ, Welck M, Brown CS et al. Larval therapy from antiquity to the present day: mechanisms of action, clinical applications and future potential. Postgrad Med J, 2007; 83: 409-413.
• 14. Mumcuoğlu KY. Clinical applications for maggots in wound care. Am J Clin Dermatol, 2001; 2 (4): 219–227.
• 15. Yaman M, Gönenci R, Altuğ ME. Maggot Sağaltımının Cerrahi Alanda Kullanımı. Veteriner Cerrahi Dergisi, 2002; 8(3-4): 116-119.
• 16. Polat E. Lucilia sericata’nın larvaları ile zor iyileşen yaraların tedavisi. XV. Ulusal Parazitoloji Kongresi (Program ve Özet Kitabı). Kayseri, 18-23 Kasım, 2007; s.57-60.
• 17. Sherman RA. Maggot therapy for foot and leg wounds. Int J Low Extrem Wounds, 2002; 1: 135–142.
• 18. Nuesch R, Rahm G, Rudin W, Steffen I, Frei R et al. Clustering of bloodstream infections during maggot debridement therapy using contaminated larvae of Protophormia terraenovae. Infection, 2002; 30: 306–309.
• 19. Wolff H, Hansson C. Rearing larvae of Lucilia sericata for chronic ulcer treatment-an improved method. Acta Derm Venereol., 2005; 85: 126-131.
• 20. Jones G, Wall R. Maggot-therapy in veterinary medicine. Res Vet Sci, 2007; 85: 394-398.
• 21. Paul AG, Ahmad NW, Lee HL, Ariff AM, Saranum M et al. Maggot debridement therapy with Lucilia cuprina: a comparison with conventional debridement in diabetic foot ulcers. Int Wound J, 2009; 6: 39–46.
• 22. Tantawi TI, Williams KA, Villet MH. An accidental but safe and effective use of Lucilia cuprina (Diptera: Calliphoridae) in maggot debridement therapy in Alexandria, Egypt. J Med Entomol, 2010; 47: 491–494.
• 23. Kingu HJ, Kuria SK, Villet MH, Mkhize JN, Dhaffala A et al. Cutaneous myiasis: is Lucilia cuprina safe and acceptable for maggot debridement therapy? J Cosmet Dermatol Sci App, 2012; 2: 79–82.
• 24. Mumcuoğlu K, Özkan AT. Süpüratif Kronik Yaraların Maggot Debridman Tedavisi, Türkiye Parazitol Derg., 2009; 33(4): 307 - 315.
• 25. Sherman RA. A new dressing design for treating pressure ulcers with maggot therapy. Plast Reconstruct Surg, 1997;100: 451-456.
• 26. Özalp AH. Deneysel Nekrotizan Pankreatitte Maggot Terapi (Larva Debritman Tedavisi), Uzmanlık Tezi, Konya: Necmettin Erbakan Üniversitesi Meram Tıp Fakültesi Genel Cerrahi Anabilim Dalı, 2013.
• 27. Fleischmann W, Thoener B. Biobag - a live wounddressing containing maggots. Fifth International Conference on Biotherapy, Wurzburg, Germany, June 29-July, 2000; p. 8.
• 28. Blake FAS, Abromeit N, Bubenheim M, Li L, Schmelzle R. The biosurgical wound debridement: experimental investigation of efficiency and practicability. Wound Repair Regen, 2007; 15: 756-761.
• 29. Kočišová A, Čonková E, Pistl J, Toporčák J. First non-conventional veterinary treatment of skin infections with blowfly larvae (Calliphoridae) in Slovakia. Bull Vet Inst Pulawy., 2003; 47: 487-490.
• 30. Wolff H, Hansson C. Larval therapy – an effective method of ulcer debridement. Clin. Exp. Dermatol., 2003; 28: 134-137.
• 31. Bowling FL, Salgami EV, Boulton AJM. Larval therapy: a novel treatment in eliminating methicillin-resistant Staphylococcus aureus from diabetic foot ulcers. Diabetes Care, 2007; 30(2): 370-371.
• 32. Sherman RA, Morrison S, Ng D. Maggot debridement therapy for serious horse wounds– a survey of practitioners. The Vet J, 2007a; 174: 86-91.
• 33. Lepage OM, Doumbia A, Perron-Lepage MF, Gangl M. The use of maggot debridement therapy in 41 equids. Equine Vet J., 2012; 44(43): 120-125.
• 34. Steenvoorde P, Jukema GN. The antimicrobial activity of maggots: in-vivo results. J Tissue Viability, 2004; 14(3): 97-101.
• 35. European wound management association (EWMA). Position document: management of wound infection. London: MEP Ltd. 2006.
• 36. Huberman L, Gollop N, Mumcuoğlu K et al. Antibacterial properties of whole body extracts and haemolymph of Lucilia sericata maggots, J Wound Care., 2007a; 16(3): 123-127.
• 37. Huberman L, Gollop N, Mumcuoğlu K et al. Antibacterial substances of low molecular weight isolated from the blowfly, Lucilia sericata, Med Vet Entomol., 2007b; 21(2): 127-131.
• 38. Bexfield A, Bond AE, Roberts EC et al. The antibacterial activity against MRSA strains and other bacteria of a <500Da fraction from maggot excretions/secretions of Lucilia sericata (Diptera: Calliphoridae), Microbes Infect., 2008; 10(4): 325-333.
• 39. Barnes KM, Dixon RA, Gennard DE. The antibacterial potency of the medicinal maggot, Lucilia sericata (Meigen): Variation in laboratory evaluation, J. Microbiol. Methods., 2010; [Epub ahead of print].
• 40. Polat E, Çakan H, Aslan M, Sirekbasan S, Kutlubay Z ve ark. Detection of anti-leishmanial effect of Lucilia sericata larval secretions in vitro and in vivo on Leishmania tropica: First work. Exp Parasitol., 2012; 132: 129–134.
• 41. Polat E, Kutlubay Z. Meglümin Antimoniat Tedavisine Dirençli Dört Kutanöz Leishmaniosis Olgusu. Turkiye Parazitol Derg, 2014; 38: 177-80.
• 42. Kerridge A, Lappin-Scott H, Stevens JR. Antibacterial properties of larval secretions of the blowfly, Lucilia sericata. Med Vet Entomol, 2005; 19: 333–337.
• 43. Bonn D. Maggot therapy: an alternative for wound infection. Lancet, 2000; 356: 1174.
• 44. Bexfield A, Nigam Y, Thomas S, Ratcliffe NA. Detection and partial characterization of two antibacterial factors from the excretions/secretions of the medicinal maggot Lucilia sericata and their activity against methicillin-resistant Staphylococcus aureus (MRSA). Microbes Infect, 2004; 6: 1297–1304.
• 45. Jaklic D, Lapanje A, Zupancic K, Smrke D, Gunde-Cimerman N. Selective antimicrobial activity of maggots against pathogenic bacteria. J Med Microbiol, 2008; 57(5): 617 - 625.
• 46. Horobin AJ, Shakesheff KM, Pritchard DI. Maggots and wound healing: an investigation of the effects of secretions from Lucilia sericata larvae upon the migration of human dermal fibroblasts over a fibronectin-coated surface. Wound Repair Regen, 2005; 13(4): 422-433.
• 47. Chambers L, Woodrow S, Brown AP, Harris PD, Phillips D et al. Degradation of extracellular matrix components by defined proteinases from the greenbottle larva Lucilia sericata used for the clinical debridement of non-healing wounds. Br J Dermatol, 2003; 148: 14-23.
• 48. Beasley WD, Hirst G. Making a meal of MRSA – the role of biosurgery in hospital-aquired infection. J. Hosp. Infect., 2004; 56: 6-9.
• 49. Thomas S, Andrews AM, Hay NP, Bourgoise S. The anti-microbial activity of maggot secretions: results of a preliminary study. J Tissue Viability, 1999; 9: 127–132.
• 50. Arora S, Baptista C, Lim CS. Maggot metabolites and their combinatory effects with antibiotic on Staphylococcus aureus. Ann Clin Microbiol Antimicrob, 2011;10(6).
• 51. Mumcuoğlu KY. Miller J, Mumcuoğlu M. Friger M, Tarshis M. Destruction of bacteria in the digestive tract of the maggot of Lucilia sericata. J. Med. Entomol., 2001; 38(2): 161-166.
• 52. Wollina U, Liebold K, Schmidt WD et al. Biosurgery supports granulation and debridement in chronic wounds-clinical data and remittance spectroscopy measurement, Int J Dermatol, 2002; 41(10): 635-639.
• 53. Dumville JC, Worthy G, Jm B, Cullum N, Dowson C et al. on behalf of the VenUS II team Larval therapy for leg ulcers (VenUS II): randomised controlled trial. Br Med J, 2009; 338: 1047–1050.
• 54. Mumcuoğlu KY, Davidson E, Avidan A, Gilead L. Pain related to maggot debridement therapy. J Wound Care, 2012; 21: 400, 402, 404–405.
• 55. Sherman RA, Shapiro CE, Yang RM. Maggot therapy for problematic wounds: uncommon and off-label applications. Adv Skin Wound Care, 2007b; 20: 602–610.
• 56. Sherman RA, Stevens H, Ng D, Iversen E. Treating wounds in small animals with maggot debridement therapy: a survey of practitioners. Vet J, 2007c; 173: 138–143.